Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04920682 |
| Other study ID # |
CAAE 39680120.7.0000.5373 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
Phase 4
|
| First received |
|
| Last updated |
|
| Start date |
June 1, 2021 |
| Est. completion date |
August 21, 2021 |
Study information
| Verified date |
May 2022 |
| Source |
Pontificia Universidade Catolica de Sao Paulo |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The administration of acetylcholinesterase inhibiting agents (such as neostigmine) has been
used to reverse the muscle paralysis induced by non-depolarizing neuromuscular blocking
agents. It is not well known whether there is a difference between the time required for
complete reversion of moderate neuromuscular blockade (NMB) after the administration of
neostigmine in usual doses when compared to the reversion of superficial NMB with the use of
a reduced dose of the same agent (excessive doses of neostigmine administered during
superficial blocks may cause paradoxical muscle weakness). The aim of the present study will
be to compare, by means of a prospective, randomized, controlled and double-blind clinical
trial, the times necessary for the reversion of moderate block with neostigmine 60 mcg / kg
or for superficial block to reach values of T4 / T1> 0.9 using neostigmine 30 mcg / kg.
Description:
INTRODUCTION One of the most frequent events after performing general anesthesia is the
incomplete recovery from NMB. 1 Unfortunately, in addition to the unpleasant and unwanted
sensation, post-operative residual muscle weakness can generate potentially more serious
problems such as difficulty swallowing, airway obstruction, the occurrence of hypoxemia and
pulmonary aspiration. 2,3 Hence, the importance of ensuring a complete reversal of
non-depolarizing neuromuscular blocking agents before extubation. Traditionally, the
administration of acetylcholinesterase inhibiting agents (such as neostigmine) has been used
to reverse the muscle paralysis induced by the use of non-depolarizing neuromuscular blocking
agents, but there are limitations related to the antagonism of deep neuromuscular blockade
4,5 or the occurrence of paradoxical effect, when excessive doses of neostigmine are
administered during superficial blocks, causing muscle weakness 6,7. In view of this
scenario, the need for quantitative assessment of neuromuscular monitoring through the
stimulation of peripheral nerves is widely recognized to evaluate NMB reversal.3 During deep
NMB [Train-of-Four (TOF) = 0 ; Post-Tetanic Count (PTC)> 1], the administration of
neostigmine is likely to be inefficient and its administration is not indicated. In these
cases, it would be more prudent to wait for the spontaneous regression of the NMB to less
intense levels, when the action of neostigmine becomes more effective and safer.1 Even so,
when there is light neuromuscular block (TOF = 4; T4 / T1> 0.4), the use of lower doses of
neostigmine should be considered, as there is a risk of inducing paradoxical muscle weakness.
9 It is not well known whether there is a difference between the time required for complete
reversion of moderate NMB after the administration of neostigmine in usual doses when
compared to the reversion of superficial NMB with the use of a reduced dose of the same
agent. The aim of the present study will be to compare, by means of a prospective,
randomized, controlled and double-blind clinical trial, the times necessary for the reversion
of TOF = 3 (moderate block) to T4 / T1 values> 0.9 (with neostigmine 60 mcg / kg) or for T4 /
T1> 0.4 (superficial block) to reach values of T4 / T1> 0.9 (with neostigmine 30 mcg / kg).
In addition, the times required for the reversion of TOF = 3 to T4 / T1> 0.4 and TOF = 3 to
T4 / T1 = 1 will be evaluated, in addition to the probability of reversing the NMB in less
than 10 minutes.
METHODS
After approval by the Research Ethics Committee of School of Medical and Health Sciences,
Pontifical Catholic University of São Paulo (Sorocaba, São Paulo - Brazil), patients
undergoing general anesthesia for nose and ear surgery at Hospital Santa Lucina will be
enrolled to this prospective and randomized clinical trial. Patients aged between 18 and 65
years and physical status according to the American Society of Anesthesiologists I and II
will be included. The exclusion criteria will be: (i) refusal to participate in the study;
(ii) presence of kidney, liver or neuromuscular disease; (iii) contraindication to the use of
any of the drugs used in the study or (iv) body mass index (BMI) ≥ 30. Patients will be
randomly divided into four groups according to the moment of NMB reversal and the doses of
neostigmine and atropine that will be administered:
- Group M (reversion with moderate NMB): administration of neostigmine 60 mcg/kg and
atropine 30 mcg/kg when TOF (Train-of-Four) = 3 and saline when TOF (T4 / T1)> 0.4.
- Group S (reversion with superficial NMB): administration of 0.9% saline solution (SF)
when TOF = 3 and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)> 0.4.
- Group N (two-step reversal): neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF = 3
and neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOF (T4 / T1)> 0.4 .
- Group C (control): administration of 0.9% saline solution (SF) when TOF = 3 and when TOF
(T4 / T1)> 0.4.
For each patient, an opaque envelope will be prepared, sealed and numbered sequentially
containing the group to which the patient will be allocated. A list of random numbers
generated by computer (www.random.org), in blocks of 1: 1: 1: 1, will be used for this
purpose. No collaborator in the operating room, surgeon or anesthesiologist involved in the
control of anesthesia and data collection will be aware of the content of the solutions
(neostigmine with atropine or saline). An anesthesiologist not involved in the study will be
responsible for preparing the solutions:
- solution 1 (administered when TOF = 3) - neostigmine 60 mcg/kg and atropine 30 mcg/kg
diluted with SF until 20 mL (group M); neostigmine 30 mcg/kg and atropine 15 mcg/kg
diluted with SF to 20 mL (group N) or 0.9% SF 20 mL (group S)
- solution 2 (administered when T4 / T1> 0.4) - neostigmine 30 mcg/kg and atropine 15
mcg/kg diluted with SF until 20 mL (group M or N) or SF 0.9% 20 mL (group S)
Study sequence Anesthesia No patient will receive pre-anesthetic medication. After filling
out the consent form and arrival at into the operating room, standard American Society of
Anesthesiologists monitors will be applied. A venous access will be obtained in an upper limb
contralateral to the NMB monitoring. After pre-oxygenation, anesthesia induction will be
performed with 0.5 mcg/kg/min remifentanil for 3 minutes followed by propofol bolus (2.0
mg/kg) and cisatracurium 0.10 mg/kg. Maintenance will be performed with remifentanil (0.3
mcg/ kg/min) and propofol (4 to 6 mg/kg/h). Tracheal intubation will be performed when T1 was
less than 5%. The ideal weight will be used to calculate the dose of cisatracurium and
neostigmine. Ventilation will be controlled, with the tidal volume and respiratory rate
adjusted to maintain PETCO2 between 30 and 40 mmHg. When an inadequate anesthesia plan is
suspected (movement, sweating, tachycardia, increase in blood pressure> 10% of pre-induction
values), the rate of propofol infusion will be increased and if the adequacy is not
sufficient, the rate of infusion of remifentanil. Patients who have a systolic blood pressure
decrease greater than 30% or heart rate less than 50 bpm will be treated with ephedrine (10
mg) and atropine (0.5 mg), respectively. Hydration will be performed with 0.9% saline (500 ml
in the first 30 minutes and 2 ml / kg / h in the following hours). The central temperature
will be maintained above 35 degrees Celsius and the peripheral temperature (tenar eminence of
the monitored palm) above 32 degrees Celsius. The reversal of the NMB will be performed when
TOF = 3 and / or T4 / T1> 0.4 through the administration of the previously prepared solution.
Monitoring of neuromuscular block The NMB will be monitored by the acceleromyography method
(TOF Watch; Schering-Plow) as recommended for use in clinical research. 10 The acceleration
transducer will be fixed on the volar side in the distal phalanx of the thumb. The venous
access and the BP cuff will be positioned on the arm opposite the limb used to monitor the
NMB. After cleaning the skin along the path of the ulnar nerve in the forearm, the electrodes
will be positioned at the height of the wrist with a distance between 3 to 6 cm between them.
Calibration will be performed after automatically after a 50 Hz tetanic stimulus for 5
seconds. The stimulation (TOF 2 Hz 1.5 seconds, supramaximal stimuli, square wave and
duration of 0.2 msec) will be applied every 15 seconds for 2 minutes before the
administration of cisatracurium. No additional doses of neuromuscular blockade will be
administered. As soon as the third response to TOF is obtained, solution number 1 will be
administered and the times between the administration of cisatracurium and TOF = 3 and until
this value reaches T4 / T1 = 0.4 will be recorded. At this point, the second solution will be
administered and the time until the value of the T4 / T1 ratio reaches a value equal to 0.9
will also be recorded. T1> 0.9. Secondary outcomes will be considered, the probability of
reversing the NMB in less than 10 minutes and the time required for the reversion of the
moderate NMB (TOF = 3) to T4 / T1 = 1. The sample size will be based on a previous study that
determined the need for 12 patients per group to detect with a power of 90% and alpha error
of 5% a difference between groups equal to or greater than 1.3 standard deviations.11
Considering the possible losses, 60 patients will be randomized.
